RCM
SNDX icon

RA Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

RA Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,023,067
Closed -$22.9M – 98
2021
Q1 		$22.9M Hold
1,023,067
– – 0.34% 53
2020
Q4 		$22.8M Hold
1,023,067
– – 0.32% 55
2020
Q3 		$15.1M Hold
1,023,067
– – 0.28% 54
2020
Q2 		$15.2M Buy
+1,023,067
New +$15.6M 0.3% 44

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RA Capital Management's SNDX Position: Q2 2021 in Review

RA Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q2 2021, closing a stake of 1,023,067 shares — an estimated $22.9M sold.

RA Capital Management first reported a position in SNDX in Q2 2020 and held it in 4 quarters. The position peaked at $22.9M in Q1 2021. 115 funds tracked by Wall St. Rank hold SNDX as of Q2 2021.

  • RA Capital Management reported no remaining Syndax Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • RA Capital Management sold 1,023,067 Syndax Pharmaceuticals shares in Q2 2021, an estimated $22.9M.
  • RA Capital Management first reported a position in Syndax Pharmaceuticals in Q2 2020 and held it in 4 quarters.
  • RA Capital Management's Syndax Pharmaceuticals position peaked at $22.9M in Q1 2021.
  • 115 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2021.

Based on RA Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.